Short answer
The evidence is weak. Fulvic acid from shilajit stops tau protein clumping in the test tube, and rodent studies show effects on brain chemistry. The only human trial tested a blend of Andean shilajit and B vitamins in 82 people with Alzheimer's: apathy improved, but the blend makes it impossible to credit shilajit.
Weak evidence
Small, short or poorly controlled human studies, or animal and lab work only. How we grade evidence
Brain health is one of the most hopeful-sounding claims about shilajit, and one of the least proven. The interest comes mainly from a research group in Chile, which showed that fulvic acid, a major component of shilajit, can stop tau protein from clumping in the test tube. Tau tangles are one of the hallmarks of Alzheimer’s disease.
The same group has since tested a product combining Andean shilajit with B vitamins in people with Alzheimer’s. That makes this a little stronger than “lab studies only”, but not by much. We grade the evidence as weak.
What does fulvic acid do to tau protein?
In laboratory experiments, it blocks tau from forming the filaments seen in Alzheimer’s and can break up filaments that have already formed. Researchers at the University of Chile showed this using purified proteins in solution, studying the fibrils with atomic force microscopy (Cornejo et al., 2011). A later review by the same team described fulvic acid as shilajit’s main active principle and called for clinical trials (Carrasco-Gallardo et al., 2012).
In 2023 they reported that fractions of Andean shilajit made rat brain cells grow longer branches in culture and stopped tau aggregating after 10 days (Andrade et al., 2023).
This is a plausible starting point, but test-tube results often fail to carry over to people. Nobody has shown that fulvic acid from oral shilajit gets into the human brain.
Has shilajit been tested in people with Alzheimer’s?
Only as part of a blend. BrainUp-10 combines Andean shilajit with B-complex vitamins (Calfio et al., 2020). After earlier safety and pilot work, some of it described in a 2012 review by the same group (Carrasco-Gallardo et al., 2012, Arch Med Res), the developers ran a multicentre, randomised, double-blind, placebo-controlled trial in Chile (Guzman-Martinez et al., 2021).
| Feature | Detail |
|---|---|
| Participants | 82 people with mild to moderate Alzheimer’s |
| Main outcome | Apathy (loss of interest and motivation) |
| Apathy result | Significantly lower with BrainUp-10 at weeks 4 and 12 |
| Memory test (MMSE) | Improved at week 24 compared with patients’ own starting scores |
| Other findings | Lower homocysteine; behavioural symptom scores improved |
| Safety | No compound-related side effects reported |
The limitations are significant:
- It’s a combination product. B vitamins affect brain health and homocysteine in their own right, so the trial can’t tell us what shilajit contributed.
- The memory result is reported against patients’ starting scores. The summary says it met the trial’s pre-set superiority criteria but gives no direct figure against placebo.
- The developers ran it. The trial came from the same research group that created BrainUp-10. That doesn’t make the results wrong, but independent replication matters.
- Apathy was the main measure, not memory or the progression of Alzheimer’s.
What do animal studies show?
A scattering of rodent studies point to effects on brain chemistry, none of them directly about memory in healthy animals:
- In rats injected with shilajit for seven days, activity of the enzyme that breaks down acetylcholine, a chemical messenger involved in memory, fell in the basal forebrain (Schliebs et al., 1997).
- In rats with head injuries, shilajit injections reduced brain swelling and pressure inside the skull and improved neurological scores (Khaksari et al., 2013).
- In rats and mice, shilajit given by mouth for 15 days reduced chemically and electrically triggered seizures (Durg et al., 2015).
Injected doses and induced injuries in rodents are far removed from a person taking a daily supplement.
Does shilajit help focus or “brain fog”?
There is no research on this. It’s a common marketing claim, but we found no human or animal study that measured focus, concentration or brain fog.
What should you do if you’re worried about memory?
See a GP. Memory problems have many causes, some treatable, such as low vitamin B12, thyroid problems, depression or medicine side effects. Early assessment also gives access to support and treatment if dementia is diagnosed.
If someone with dementia wants to try shilajit, check with their doctor or pharmacist first (see drug interactions) and choose a product tested for heavy metals, since metals such as lead are themselves harmful to the brain (heavy metals in shilajit). Fulvic acid is covered in more depth on our fulvic acid page, and the benefits overview compares every claim.
Frequently asked questions
Can shilajit prevent Alzheimer's disease?
There is no evidence that it can. No study has followed healthy people taking shilajit to see whether fewer develop dementia.
Does shilajit improve memory in healthy people?
No human study has tested this. Claims about memory come from rodent experiments and laboratory work on fulvic acid.
Can someone with dementia take shilajit alongside their medicines?
Only after talking to their doctor or pharmacist. Shilajit hasn't been studied alongside dementia medicines, and people with dementia often take several drugs. See our drug interactions page.
References
- Cornejo A et al. Fulvic acid inhibits aggregation and promotes disassembly of tau fibrils associated with Alzheimer's disease. J Alzheimers Dis. 2011;27(1):143-53.pubmed.ncbi.nlm.nih.gov
- Carrasco-Gallardo C, Guzmán L, Maccioni RB. Shilajit: a natural phytocomplex with potential procognitive activity. Int J Alzheimers Dis. 2012;2012:674142.pubmed.ncbi.nlm.nih.gov
- Andrade V et al. Scaling the Andean Shilajit: A Novel Neuroprotective Agent for Alzheimer's Disease. Pharmaceuticals (Basel). 2023;16(7):960.pubmed.ncbi.nlm.nih.gov
- Guzman-Martinez L et al. Interventional Study to Evaluate the Clinical Effects and Safety of the Nutraceutical Compound BrainUp-10 in a Cohort of Patients with Alzheimer's Disease: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial. J Alzheimers Dis. 2021;81(3):1231-1241.pubmed.ncbi.nlm.nih.gov
- Calfio C et al. The Emerging Role of Nutraceuticals and Phytochemicals in the Prevention and Treatment of Alzheimer's Disease. J Alzheimers Dis. 2020;77(1):33-51.pubmed.ncbi.nlm.nih.gov Describes BrainUp-10 as Andean shilajit with B-complex vitamins.
- Carrasco-Gallardo C et al. Can nutraceuticals prevent Alzheimer's disease? Potential therapeutic role of a formulation containing shilajit and complex B vitamins. Arch Med Res. 2012;43(8):699-704.pubmed.ncbi.nlm.nih.gov
- Schliebs R et al. Systemic administration of defined extracts from Withania somnifera (Indian Ginseng) and Shilajit differentially affects cholinergic but not glutamatergic and GABAergic markers in rat brain. Neurochem Int. 1997;30(2):181-90.pubmed.ncbi.nlm.nih.gov
- Khaksari M et al. The Effects of Shilajit on Brain Edema, Intracranial Pressure and Neurologic Outcomes following the Traumatic Brain Injury in Rat. Iran J Basic Med Sci. 2013;16(7):858-64.pubmed.ncbi.nlm.nih.gov
- Durg S et al. Antiepileptic and antipsychotic activities of standardized Śilājatu (Shilajit) in experimental animals. Anc Sci Life. 2015;35(2):110-7.pubmed.ncbi.nlm.nih.gov
First published 16 October 2026. Spotted an error? Tell us and we'll correct it. Read our editorial policy.
